INTRODUCTION
Ebola virus (EBOV) is a nonsegmented negative-sense RNA virus belonging to the ebolavirus genus in the family Filoviridae. These viruses are highly pathogenic and cause Ebola virus disease (EVD), previously referred to as Ebola hemorrhagic fever with case fatality rates up to 90% (Feldmann and Geisbert, 2011; Feldmann and Kiley, 1999) . During 2014 Africa experienced the largest EBOV outbreak in history that resulted in over 28,000 cases and 11,000 deaths (Coltart et al., 2017) . Alarmingly, the most recent EBOV-Kivu outbreak in the Democratic Republic of the Congo (DRC) has a reported 3,224 confirmed and probable cases of EVD and 2,152 deaths as of October 16, 2019 and does not currently show signs of abating (https://www.who.int/csr/don/02-may-2019-ebola-drc/en/). Currently, there are no approved vaccines or therapeutics to prevent or treat EVD; this fact combined with these unprecedented outbreaks in recent years underscores the urgent need to develop a wide variety of effective treatment strategies.
The current armamentarium of treatment options against EBOV primarily consists of small molecules and immunotherapeutics (Edwards and Basler, 2019; King et al., 2019) . Of the reported small molecules that demonstrate anti-EBOV activity, the nucleoside analogs BXC4430, GS-5734, and Favipriravir have shown anti-EBOV activity in in vivo infection models (Bixler et al., 2018; Warren et al., 2014 Warren et al., , 2016 . Similarly, numerous reports have demonstrated that monoclonal antibodies (MAbs) are effective at inhibiting infection (Brannan et al., 2019; Furuyama et al., 2016; Howell et al., 2017; King et al., 2019; Marzi et al., 2012; Pettitt et al., 2013; Qiu et al., 2012; Audet et al., 2014) . These MAbs target the EBOV glycoprotein (GP), which acts as an attachment factor, binding the host receptor Neimann-Pick C1 (NPC1) and mediating viral-host cell membrane fusion within the endosomal compartment (Davey et al., 2017; Carette et al., 2011; Cote et al., 2011; Hunt et al., 2012) . Prior to receptor engagement, GP is cleaved by host cathepsins (Cat) B and L (Chandran et al., 2005; Schornberg et al., 2006) . Cleavage of GP by CatB is required for GP-NPC1 binding and subsequent endosomal fusion (Miller et al., 2012) . As a result, targeting GP endosomal processing and receptor binding can serve as an effective method of EBOV inhibition. Indeed, inhibitors of CatB/L or blockade of GP-NPC1 binding have shown efficacy against EBOV infection (Carette et al., 2011; Chandran et al., 2005; Elshabrawy et al., 2014; Herbert et al., 2015; Schornberg et al., 2006; Zhang et al., 2018) .
Antimicrobial peptides (AMPs, also called host defense peptides) serve as an essential component of the innate immune system, in part, owing to their pleiotropic functions in microbial killing, inflammation, and wound healing (Nakatsuji and Gallo, 2012) . The two major AMP families in mammalian cells are the defensins and the cationic cathelicidin peptides Ganz, 2002a, 2002b; Zanetti et al., 1995) . Although there are multiple defensin genes, there is only one known cathelicidin gene in humans (Lehrer and Ganz, 2002a; Sorensen et al., 1997) . The human cathelicidin, hCAP-18, is abundantly expressed in neutrophils, monocytes, and epithelial cells of skin and mucosal membranes (Agerberth et al., 2000; Sorensen et al., 1997) . hCAP-18 is stored as an inactive precursor and upon stimulation is processed to generate the active peptide LL-37 (Sorensen et al., 2001) . Interestingly, besides its broad anti-bacterial property, LL-37 can also inhibit several viruses, including Influenza A virus, human rhinovirus, human adenovirus, and human immunodeficiency virus (Bergman et al., 2007; Currie et al., 2013; Uchio et al., 2013; Sousa et al., 2017) . Recently, it has been demonstrated that LL-37-derived AMPs inhibit Zika virus infection, although the mechanisms are not well defined (He et al., 2018) . Nevertheless, these studies suggest LL-37 AMPs can serve as viable antiviral therapeutics.
In the present study, we show that human LL-37 and in particular, two engineered LL-37 variants function as inhibitors for EBOV infection. AMPs are known to have both direct and indirect antimicrobial effects; therefore, we explored the mechanism of action. We found that these AMPs impaired early events during EBOV infection but had no effect on virus replication. Further analysis revealed that AMPs impaired CatB-mediated cleavage of EBOV GP. Taken together, these data demonstrate that engineered AMPs are potent inhibitors of EBOV entry.
RESULTS

Engineered AMPs Inhibit EBOV Pseudovirion Infection of Cell Lines and Human Primary Macrophages
Since EBOV is a highly lethal agent, EBOV-GP pseudotyped viruses based on attenuated vectors have been widely used in research laboratories. Here we used a recombinant vesicular stomatitis virus (rVSV) expressing EBOV-GP and green fluorescence protein (rVSV-EBOVgp-GFP, in short, VSV-eGP) as an experimental system to test the effects of AMPs on EBOV-GP-mediated infection. Initially, we screened 20 AMPs including the parent human LL-37 and its engineered variants. We found that two engineered LL-37 variant peptides 17BIPHE2 (in short 17BI) and GI-20d were most potent in inhibiting VSV-eGP infection (data not shown). Therefore, we decided to focus on these two peptides and the relevant control peptides in this study (listed in Figure 1 ). The parent LL-37 peptide was included as a baseline control. Peptides GF-17 and GI-20 containing the native sequences for 17BI and GI-20d, respectively, were derived from the major antimicrobial region of LL-37 Wang et al., 2008) . Peptide 17BI was engineered with three Dform amino acids and two biphenylalanines based on the sequence of GF-17 . GI-20d is a novel peptide engineered with all D-form amino acids with identical sequence to GI-20. Peptide RI-10 is an inactive LL-37 derivative with only 10 amino acids, serving as a negative control .
HeLa cells were infected with VSV-eGP viruses together with individual AMPs (at 5 mM) or an EBOV neutralizing mAb 13C6 as a positive control. At 20 h post infection, cells were harvested for flow cytometry analysis All the engineered AMPs are C-terminally amidated and derived from the sequence of human native LL-37 (hLL-37). 17BI is a short name for 17BIPHE2 as previously published.
to determine percentages of cells positive for GFP as the measurement of VSV-eGP infection. Parent LL-37 and engineered AMPs (except the negative control RI-10) displayed different degrees of inhibitory effects on VSV-eGP infection (Figure 2A ). Peptides 17BI and GI-20d were the most potent in inhibiting VSV-eGP infection with over 80% inhibition at 5 mM, whereas peptides LL-37, GF-17, and GI-20 led to 20%-44% inhibition under the same condition ( Figure 2A ). All these peptides showed dose-dependent inhibition of VSV-eGP infection in HeLa cells ( Figure 2B ).
Because human macrophages are a primary target during natural EBOV infection, we next examined whether these AMPs inhibit VSV-eGP infection in human primary macrophages (Bray and Geisbert, 2005; Gupta et al., 2007) . CD14 + monocytes were freshly purified from human blood samples and differentiated to macrophages by treatment with macrophage-colony-stimulating factor (M-CSF) (Murray et al., 2014) . Macrophages were then infected with VSV-eGP together with mAb 13C6 or AMPs. Similar to the results in HeLa cells, all the AMPs (except the RI-10 negative control) displayed dose-dependent inhibition of VSV-eGP infection in macrophages ( Figure 2C ). Peptides 17BI and GI-20d were the most potent and almost completely inhibited VSV-eGP infection in macrophages at 10 mM ( Figure 2C ). We next determined the (B) AMPs inhibited pseudo-EBOV (VSV-eGP) infection in HeLa cells in a dose-dependent manner. VSV-eGP viruses were added to HeLa cells together with monoclonal antibody 13C6 (at 5, 10, or 20 mg/mL) or individual AMPs (at 2.5, 5, or 10 mM). After 20 h of culture, HeLa cells were harvested for flow cytometry analysis to measure viral infection. ***, p < 0.001 by two-way ANOVA test. (C) AMPs inhibit pseudo-EBOV (VSV-eGP) infection in human primary macrophages. Human monocytes were freshly purified from blood and differentiated to macrophages by culturing the cells in media containing M-CSF. Macrophages were then infected with VSV-eGP in the presence of mAb 13C6 (at 5, 10, or 50 mg/mL) or AMPs (at 2.5, 5, or 10 mM). Cells were analyzed by flow cytometry at 20 h post infection. *, p < 0.05; **, p < 0.01 by two-way ANOVA test. (D) A summary of the efficacy and toxicity of the AMPs in HeLa cells and human primary macrophages. Cells were infected with VSV-eGP together with AMPs at different concentrations ranging from 0.1 to 50 mM and analyzed by flow cytometry at 20 h post infection to evaluate the IC 50 (half maximal inhibitory concentration). To measure cytotoxicity, cells were treated alone with the AMPs at different concentrations for 20 h. Cell viability was measured by MTT cell proliferation assay to determine the TC 50 (half maximal toxicity concentration).
half-maximal concentration of inhibition (IC 50 ) and half-maximal concentration of cell toxicity (TC 50 ) of these AMPs in HeLa cells and primary macrophages. All the AMPs displayed lower IC 50 concentrations in HeLa cells than in macrophages, although they also displayed slightly lower TC 50 concentrations in HeLa cells than in macrophages ( Figure 2D ). Among the parent LL-37 and its engineered variants, peptide GI-20d had the most favorable therapeutic window in both HeLa cells and primary macrophages (with an IC 50 of 0.99 mM and TC 50 of 18.8 mM in HeLa cells and an IC 50 of 2.2 mM and TC 50 of more than 30 mM in macrophages). Peptide 17BI also had a favorable therapeutic window with an IC 50 of 0.71 mM and TC 50 of 13.2 mM in HeLa cells and an IC 50 of 5.6 mM and TC 50 of more than 30 mM in macrophages ( Figure 2D ). We also examined the effects of AMPs on VSV-eGP infection in Vero cells, a cell line commonly used for propagating viruses and in analyzing virus infection. Similarly, the parent LL-37 and its engineered variants (except the negative control RI-10) displayed dose-dependent inhibition of VSV-eGP infection in Vero cells (Figures S1A and S1B). In agreement with our findings in HeLa cells and primary macrophages, 17BI and GI-20d were the most potent peptides in inhibition of VSV-eGP infection in Vero cells. Both peptides almost completely inhibited VSV-eGP infection at concentrations R5 mM in Vero cells (Figures S1A and S1B).
Taken together, our data show that engineered LL-37 variant peptides 17BI and GI-20d are potent inhibitors of EBOV pseudovirion infection in HeLa and Vero cells as well as in human primary macrophages.
Engineered AMPs Inhibit Wild-Type EBOV-Kiwit Infection
Given the observed potency of AMP's within our surrogate EBOV system, we next tested whether these AMPs have similar effects on wild-type (WT) EBOV infection. HeLa cells were pre-incubated with AMPs at different concentrations for 2 h and then infected with EBOV-Kiwit. At 24 h post infection, cells were fixed, permeabilized, and immuno-stained with an anti-EBOV GP antibody followed by a fluorescence-conjugated secondary antibody to identify infected cells. In agreement with our EBOV pseudovirion studies, engineered peptides 17BI and GI-20d displayed much higher potency in blocking the infection of WT EBOV than the peptides containing only L-amino acids, GF-17 and GI-20 ( Figure 3A) . Peptides 17BI and GI-20d had an IC 50 of 3 and 1.6 mM, respectively, whereas GF-17 and GI-20 both had an IC 50 of about 20 mM ( Figure 3B ). Interestingly, these AMPs did not significantly affect Marburg virus (MARV) infection under the same conditions, demonstrating the specificity of AMPs in inhibiting EBOV infection ( Figure S2 ). The inhibitory effects of engineered AMPs on WT EBOV infection further support the finding that engineered AMPs may be a new class of anti-EBOV countermeasures and highlights the consistency between WT EBOV and the surrogate systems.
Engineered AMPs Inhibit EBOV Cell Entry but Not Viral Replication
To determine potential mechanisms responsible for the inhibitory effects of LL-37-derived AMPs on EBOV infection, we next examined whether these AMPs targeted EBOV cell entry by comparing the effects of pretreatment or delayed AMP treatment of cells prior to viral infection. As previously observed ( Figure 2C ), AMPs 17BI and GI-20d, but not LL-37, GF-17, or GI-20, reduced VSV-eGP infection in human primary macrophages with over 40% inhibition at 5 mM when added at the time of infection ( Figure 4A ). Pre-treatment of macrophages with 17BI and GI-20d for 4 h prior to viral infection blocked VSV-eGP infection with similar efficacy ( Figure 4A ). However, delayed treatment of macrophages with 17BI and GI-20d peptides resulted in a time-dependent reduction of effects, with approximately 20% of inhibition when added at 4 h post infection and a complete loss of inhibition when added at 8 h post infection ( Figure 4A ). These data suggested that engineered AMP peptides may target the early cell entry stage of EBOV infection. Similar results were observed for Vero cells ( Figure S1C ).
We next used Ebola virus-like particles (VLPs) to directly test the effects of AMPs on EBOV cell entry. Ebola VLPs were produced by co-expressing the EBOV matrix protein VP40 (fused to b-lactamase) and the EBOV GP. The VLPs possess a structure and biochemical composition similar to the WT EBOV, but unlike the WT virus, lack genetic materials for virus replication. The activities of cytoplasmic b-lactamase thus represent the relative levels of productive cell entry of Ebola VLPs. Vero cells were pre-incubated with AMPs or a cathepsin B (CatB)-specific inhibitor (as a positive control) followed by Ebola VLP infection. CatB inhibitor and peptides 17BI and GI-20d displayed dose-dependent inhibition of cytoplasmic b-lactamase activity, providing direct evidence that engineered AMPs inhibit productive EBOV cell entry ( Figure 4B ).
After entering the cytoplasm, EBOV undergoes replication to amplify its genetic material in order to produce progeny virions. In the absence of WT virus, replication can be studied using an EBOV mini-genome system (Cressey et al., 2017) . We next examined the effects of AMPs on EBOV replication using this system. The EBOV minigenome plasmids (encoding firefly luciferase reporter gene flanked by the leader and trailer sequences from EBOV genome) were co-transfected into HeLa cells with four supporting plasmids encoding EBOV replication complex components NP, L, VP35, and VP30 and a plasmid encoding Renilla luciferase (for normalization of transfection efficiency). The ratio of firefly to Renilla luciferase represented the relative levels of EBOV mini-genome replication. None of the tested AMPs (at 5 mM) led to a significant change of the ratio of firefly to Renilla luciferase, whereas the positive control Ribavirin significantly reduced the ratio ( Figure 4C ). Our data suggest that LL-37 and its engineered variants do not affect EBOV replication in the mini-genome system.
Collectively, the results suggest that engineered LL-37 variant peptides, 17BI and GI-20d, block EBOV cell entry but not viral replication.
LL-37 and Engineered AMPs Block CatB-Dependent Processing of EBOV-GP
Productive EBOV cell entry and infection requires the processing and cleavage of EBOV-GP by cathepsins within the endosome. We therefore next tested whether AMPs block CatB-and CatL-mediated cleavage of EBOV-GP. CatB was pre-incubated with AMPs or a known CatB inhibitor (CA-074 methyl ester, as a positive control) in a pH 5.0 buffer before the addition of EBOV GP protein. The reaction mixture was then subjected to western blot analysis to analyze EBOV GP proteolytic cleavage. As expected, EBOV GP (about 110 kD) was cleaved by CatB and generated a 19-kD product in a denaturing gel ( Figure 5A) . CatB inhibitor and all the tested AMPs (except the negative control RI-10) effectively blocked the processing of EBOV-GP by CatB ( Figure 5A ). However, none of the tested AMPs had any effects on the processing of EBOV-GP by CatL under the same conditions ( Figure 5B ).
Using standard CatB and CatL substrates, we next tested whether the AMPs block the intrinsic activity of CatB and CatL. All the tested AMPs (except RI-10 negative control) inhibited CatB-mediated cleavage of Z-Arg-Arg-AMC in a dose-dependent manner ( Figure S3A ). Engineered peptide 17BI is the most effective in inhibiting CatB activity among the tested peptides with an IC 50 of 6 mM ( Figure S3B ). However, none of the peptides had inhibition effects on CatL-mediated cleavage of Z-Phe-Arg-AMC ( Figure S3C ). The data demonstrated that LL-37 and engineered AMPs directly inhibit the intrinsic enzymatic activity of CatB, but not that of CatL.
AMPs Composed of L-Amino Acids Are Susceptible to Degradation by Cathepsin S (CatS) and Blockage of CatS Enhances AMP Inhibition of EBOV Infection
Notably, the parent LL-37 and derivatives GF-17 and GI-20 had efficacy similar to engineered variants 17BI and GI-20d in their inhibition of CatB-mediated EBOV GP (eGP) cleavage in vitro; however, their efficacy in inhibiting EBOV infection in cells was much lower than the variants containing D-amino acids. We postulated that AMPs composed of L-amino acids are more susceptible to degradation by proteolytic enzymes inside cells, thus reducing their availability to block CatB in vivo. To test this hypothesis, we examined whether the AMPs were susceptible to CatS cleavage in an in vitro reaction. CatS was used because it is the most abundant cathepsin in the endosome/lysosome of macrophages and LL-37 has been shown to be an excellent substrate of CatS (Shi et al., 1992; Andrault et al., 2015) . All the AMPs composed of L-amino acids only (LL-37, GF-17, GI-20, and RI-10) were completely degraded by CatS treatment in the reaction, whereas AMPs containing D-amino acids (17BI and GI-20d) were resistant to CatS cleavage ( Figure 6A) . The data indicate that AMPs composed of L-amino acids are susceptible to degradation by CatS upon entering cells. We then hypothesized that blockage of CatS may stabilize these AMPs inside cells, thus Figure 5 . LL-37 and Engineered AMPs Block the Cleavage of EBOV GP by CatB, but Not by CatL (A) LL-37 and engineered AMPs blocked CatB-dependent cleavage of EBOV GP. CatB was pre-incubated with the CatB inhibitor (CA-074 methyl ester at 50 mM, as a positive control) or AMPs (at 10 mM) in 100 mM sodium acetate buffer pH 5.0 at 37 C for 30 min. Ebola GP protein was added to the reaction and incubated at 37 C for 1 h. The reaction mixtures were boiled in SDS-PAGE loading buffer and applied to denatured SDS PAGE followed by western blot with anti-Ebola GP mAb 13C6 (to detect the 110 kD full-length GP) and rabbit anti-Ebola GP polyclonal antibodies (to detect the 19 kD cleaved GP product). (B) None of the tested AMPs blocked CatL-dependent cleavage of EBOV GP. The same reaction was performed as in (A) except using CatL instead of CatB.
making them available to inhibit CatB-mediated EBOV entry. To test the hypothesis, Vero cells were pretreated with a CatS inhibitor for 2 h, followed by the addition of AMPs and VSV-eGP. CatS inhibitor treatment significantly improved the efficacy of LL-37, GF-17, and GI-20 by 4-to 10-fold in their inhibition of VSV-eGP infection ( Figure 6B ). Notably, CatS inhibitor also improved the efficacy of 17BI and GI-20d by 1.5-to 2-fold and CatS inhibitor treatment alone resulted in 30% inhibition of VSV-eGP infection, likely due to the known ability of the inhibitor to cross-inhibit CatB.
Collectively, our data suggest that LL-37 AMPs are susceptible to enzymatic degradation inside cells and engineered AMPs with D-amino acids are more resistant to such degradation, thus more effective at inhibiting EBOV infection.
DISCUSSION
In this report, we demonstrated that engineered AMPs based on human cathelicidin LL-37 inhibit EBOV infection. Mechanistic studies revealed that these AMPs act as CatB inhibitors to block the endosomal processing of EBOV GP, thus preventing virus entry. Our results identify engineered AMPs as a potential novel class of anti-EBOV therapeutics, providing an additional avenue for combating the highly lethal EBOV.
Human cathelicidin LL-37 has several limitations as a therapeutic molecule. First, it is relatively long with 37 amino acids. Second, it can be rapidly degraded by proteases. Third, it can lose activity under certain conditions. The design of engineered LL-37 aimed to overcome these limitations. Different active regions in LL-37 have been identified in previous structure-function studies (Sigurdardottir et al., 2006; Nell et al., 2006; Braff et al., 2005; Nagaoka et al., 2002; Li et al., 2006) . We have chosen GF-17 as a template for further peptide engineering because GF-17 is the most active against methicillin-resistant Staphylococcus aureus (MRSA) among active peptides discovered previously . In another study, we found that GI-20 (with three amino acid extension at the N-terminus of GF-17) had increased activity in inhibiting HIV-1 . Based on GF-17 and GI-20, respectively, 17BI and GI-20d were designed with incorporation of D-amino acids to enhance their biostability.
Interestingly, 17BI and GI-20d are found to be more effective in inhibiting EBOV infection than the parent LL-37 and other derivative peptides. Previous studies have shown that the 17BI peptide is more resistant to chymotrypsin, bacterial V8 protease, and fungal protease K degradation than GF-17 and other peptides composed of L-amino acid . Here we show that peptides 17BI and GI-20d are more resistant to degradation by CatS, a cysteine proteinase abundant in the lysosomes of macrophages, dendritic cells, and some epithelial cells (Shi et al., 1992 (Shi et al., , 1994 . In addition, pretreatment of cells with a CatS inhibitor significantly enhanced the efficacy of parent LL-37 and its derivative AMPs compose of L-amino acids in inhibiting EBOV infection ( Figure 6 ). These results suggest the important role of CatS in mediating the instability of LL-37-based AMPs inside cells. A previous study has reported that LL-37 is an excellent substrate for CatS with seven potential cleavage sites (Andrault et al., 2015) . Therefore, we anticipate that targeted engineering of AMPs to eliminate CatS cleavage sites will produce more stable versions of AMPs that may display enhanced efficacy in inhibiting EBOV infection.
Our in vitro study showed that LL-37 and its derived AMPs were inhibitors of CatB, but not CatL, using both EBOV GP and the standard substrates for each enzyme. These results are in contrast to a previous study that claimed LL-37 was a selective inhibitor of CatL but not CatB (Andrault et al., 2015) . To address any potential experimental differences, we additionally confirmed our study results using two independent sources of CatB and CatL (one source provided cathepsins purified from the liver and the other source provided cathepsins in recombinant form). In all cases, these confirmatory experiments agreed with our original results (data not shown) and the commercially available CatB-and CatL-specific inhibitors performed as expected in our assays ( Figure S3 ).
Although endosomal cysteine proteases are required for cell entry of all filovirus family members, different viruses have distinct protease preferences (Misasi et al., 2012) . CatB is required for EBOV cell entry, whereas several studies suggest that MARV cell entry does not require CatB, although it is not clear what proteases are required (Gnirss et al., 2012; Misasi et al., 2012; Sanchez, 2007) . In agreement of those studies, we found that none of our tested AMPs significantly inhibited MARV infection ( Figure S2 ). The two D-amino acid-containing AMPs (17BI and GI-20d) that display potent inhibition of EBOV infection only have minimal inhibition of MARV infection (with an IC 50 of 41 and 25 mM, respectively). In future studies, it will be interesting to test whether these AMPs also inhibit the infection of other viruses where viral cell entry involves CatB, such as other filovirus family members (e.g., Bundibugyo virus) (Misasi et al., 2012) and Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS) coronaviruses (Elshabrawy et al., 2014) .
Notably, all the LL-37 AMPs are less efficient in inhibiting EBOV infection in macrophages than in HeLa and Vero cells (Figures 2 and S1 ). Two potential mechanisms may explain the observation. First, as professional antigen-presenting cells, macrophages likely contain an abundance of proteases such as cathepsin S; therefore, AMP peptides are less available in macrophages to inhibit viral infection. Second, it is known that primary macrophages are more refractory to EBOV infection compared with tissue-culture cell lines (i.e., Vero, HeLa). As such, EBOV macrophage infection requires a 10-fold higher MOI compared with cell lines. Therefore, it is likely that an increase in the amounts of AMPs is needed to achieve similar degrees of inhibition. Finally, it should be noted that our data are consistent with findings that EBOV neutralizing antibodies, such as 13C6, demonstrate less potency with higher IC 50 values in primary macrophages relative to cell lines.
The current promising treatment options against EBOV primarily consists of nucleoside analog small molecules and immunotherapies using neutralizing antibodies (Edwards and Basler, 2019; King et al., 2019) . It will be interesting to test whether the combined use of engineered AMPs with those therapeutic regimens will have additive efficacy, given that distinct inhibition mechanisms are involved. We anticipate that a combination of AMPs with small molecules that interfere with viral replication or with virus-neutralizing antibodies will have improved efficacy against EBOV.
In summary, our study has demonstrated the inhibitory effects of engineered LL-37 AMPs on EBOV cell entry. Future studies will test the therapeutic potential of these AMPs in well-established EBOV animal models. Because the most common route of EBOV infection is through blood or other body fluids, we anticipate that intravenous injection of engineered AMP peptides will be most effective, although topical use of the peptides could be an option to combat EBOV infection through direct skin contact. These animal studies will further confirm that engineered LL-37 AMPs are a novel class of anti-EBOV therapeutics.
Limitations of the Study
Most of the mechanistic studies were performed using EBOV surrogate systems. Follow-up experiments using live virus in animal systems are needed to extend the clinical utility of the findings. The current work was limited to a single filovirus member, future efforts should test against additional filovirus family members.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2020.100999.
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